The European/International Fibromuscular Dysplasia Registry and Initiative (FEIRI)—clinical phenotypes and their predictors based on a cohort of 1000 patients

Marco Pappaccogli 1,2,3†, Silvia Di Monaco 1†, Ewa Warchoł-Celińska 4, Aurélien Lorthioir 5, Laurence Amar 5,6, Lucas S. Aparicio 7, Christophe Beauloye 2,3, Rosa Maria Bruno 8,9, Patrick Chenu 2,3, Peter de Leeuw 10, Tine De Backer 11, Philippe Delmote 12, Zivka Dika 13, Daniel Gordin 14,15,16, Hilde Heute 17, Yoshio Iwashima 18, Jean-Marie Krzesinski 19,20, Abraham A. Kroon 19,10, Lucia Mazzola 21, Esteban Poch 22, Pantelis Sarafidis 23, Christophe Seinturier 24, Wilko Spiering 25, Laurent Toubiana 26, Patricia Van der Niepen 27, Daan van Twist 28, Adriana Visona 29,30, Jean-Claude Wautrecht 31, Helena Witowicz 4, Jianzhong Xu 32, Aleksander Prejbiš 4, Andrzej Januszewicz 4, Michel Azizi 5,6, and Alexandre Persu 2,3*, the European/International FMD Registry and Initiative (FEIRI), and the Working Group ‘Hypertension and the Kidney’ of the European Society of Hypertension (ESH)

Since December 2015, the European/International Fibromuscular Dysplasia (FMD) Registry enrolled 1022 patients

Aims

Since December 2015, the European/International Fibromuscular Dysplasia (FMD) Registry enrolled 1022 patients from 22 countries. We present their characteristics according to disease subtype, age and gender, as well as predictors of widespread disease, aneurysms and dissections.

† The first two authors contributed equally to the study.
* Corresponding author. Tel: +32 2 764 6306, +32 2 764 2533; fax: +32 2 764 8980, E-mail: alexandre.persu@uclouvain.be

Received 10 February 2020; revised 27 February 2020; editorial decision 6 April 2020; accepted 7 April 2020

Time for primary review: 1 day

Published on behalf of the European Society of Cardiology. All rights reserved. © The Author(s) 2020. For permissions, please email: journals.permissions@oup.com.
Methods and results

All patients diagnosed with FMD (string-of-beads or focal stenosis in at least one vascular bed) based on computed tomography angiography, magnetic resonance angiography, and/or catheter-based angiography were eligible. Patients were predominantly women (82%) and Caucasians (88%). Age at diagnosis was 46 ± 16 years (12% >65 years old). 86% were hypertensive, 72% had multifocal, and 57% multivessel FMD. Compared to patients with multifocal FMD, patients with focal FMD were younger; more often men, had less often multivessel FMD but more revascularizations. Compared to women with FMD, men were younger, had more often focal FMD and arterial dissections. Compared to younger patients with FMD, patients >65 years old had more often multifocal FMD, lower estimated glomerular filtration rate and more atherosclerotic lesions. Independent predictors of multivessel FMD were age at FMD diagnosis, stroke, multifocal subtype, presence of aneurysm or dissection, and family history of FMD. Predictors of aneurysms were multivessel and multifocal FMD. Predictors of dissections were age at FMD diagnosis, male gender, stroke, and multivessel FMD.

Conclusions

The European/International FMD Registry allowed large-scale characterization of distinct profiles of patients with FMD and, more importantly, identification of a unique set of independent predictors of widespread disease, aneurysms and dissections, paving the way for targeted screening, management, and follow-up of FMD.

Keywords

Fibromuscular dysplasia • Dissection • Aneurysm • Renovascular hypertension • Stroke

1. Introduction

Fibromuscular dysplasia (FMD) is an idiopathic, segmental, nonatherosclerotic and non-inflammatory disease of the musculature of the arterial walls, leading to stenosis of small- and medium-sized arteries. Besides stenosis, other manifestations of FMD, such as aneurysms, dissections, and arterial tortuosity may also be identified. Renal and cerebrovascular arteries are more frequently involved, but all medium-sized arteries may be affected.

While FMD is often asymptomatic and only diagnosed incidentally on the occasion of imaging tests performed for other reasons, in a number of cases, it may be at the origin of severe or even life-threatening complications. The clinical manifestations of FMD mostly depend on the vascular beds involved. Renal FMD may lead to hypertension, while cerebrovascular involvement may result in headache, pulsatile tinnitus, transient ischaemic attack, stroke and/or subarachnoid haemorrhage. The US and French FMD registries have substantially improved our knowledge on the demographic characteristics, classification, prevalence, and clinical manifestations of FMD. Thanks to their joint efforts, along with those of other groups around the world, our conception of FMD has evolved from a rare cause of renovascular hypertension of young women to a systemic vascular disease which may be diagnosed at all ages, both in women and men with a wide range of manifestations. Current knowledge has been summarized in the First International Consensus on diagnosis and management of FMD.

The European/International FMD registry was launched in December 2015 at the First Brussels National Meeting on FMD and subsequently endorsed by the European Society of Hypertension (ESH) in 2016. It currently includes more than 50 items concerning demographic and clinical characteristics, family history, type, site/s, associated lesions, and complications of FMD, as well as surgical or endovascular interventions. The online platform allows registering an indefinite number of visits, imaging, and vascular interventions for each patient. The European/International Registry also includes contribution from existing registries, such as the French NOMADE and the Polish ARCADIA-POL registries. Finally the Registry is also associated with a DNA and RNA biobank and contributes to important research initiatives in the field.

The present analysis incorporates data from the first 1022 patients enrolled in the European/International FMD Registry with the aim of (i) describing the characteristics of patients presenting with FMD in a large and diverse multicentre cohort; (ii) comparing clinical and FMD characteristics between different subgroups of patients (patients with multifocal vs. focal FMD; men vs. women; patients < 65 vs. ≥ 65 years old); (iii) identifying predictors of multivessel disease, and of presence of FMD-related aneurysms and/or dissections.

2. Methods

The diagnosis of FMD was based on the identification of multifocal or focal FMD lesions in at least one arterial bed by computed tomography angiography, magnetic resonance angiography and/or catheter-based angiography, as recommended in the First International FMD Consensus. Multifocal FMD was defined as the presence of alternating areas of stenosis and dilatation (‘string-of-beads’ appearance), especially in the mid- and distal segments of the artery. Focal FMD was defined as the presence of a single stenosis occurring in any part of the artery in the absence of arguments in favour of atherosclerotic, inflammatory, or genetic arteriopathies. Patients with both multifocal and focal lesions were considered as being of the multifocal subtype. In agreement with the International Consensus, multivessel FMD was defined as the presence of multifocal or focal FMD lesions in at least two different arterial beds or, alternatively, FMD-related stenosis in one vascular bed and other FMD-related lesions in one or more vascular bed(s). The following vascular beds were taken into account: cerebrovascular, renal, visceral, upper and lower extremity arteries.

Both prevalent and incident patients aged ≥18 years were eligible. Patients with suspicion of FMD only based on duplex ultrasound were excluded. Patients whose primary diagnosis was spontaneous coronary artery dissection were not eligible.

The study was approved by local and national Institutional Review Boards (IRBs), and informed consent was obtained according to national regulations. At the time of enrolment, the investigators filled an initial enrolment form in the FMD platform, including demographic characteristics (age, gender, height, and ethnicity) and clinical characteristics...
(number of pregnancies, use and duration of oral contraception, age at diagnosis of FMD, angiographic subtype of FMD, symptoms of FMD at diagnosis, and associated atheroma lesions), data concerning the first visit [seated office systolic and diastolic blood pressure (BP), body weight, serum creatinine, smoking habit, and number of antihypertensive medications], and vascular imaging (arterial beds explored, imaging modality, type, and site of lesions for each vascular bed). Furthermore, the investigators had to provide to the study coordinator (A.P.) fully anonymized images of the FMD lesion that led to the diagnosis. In case of disagreement, the diagnosis was discussed in a clinico-radiologic meeting at the coordinating centre, in cooperation with the referring investigator. The final decision to include or not the patient was made by the coordinator and his team, thus ensuring consistency in diagnostic criteria and interpretation of the images. At the time of each follow-up visit and/or imaging test performed, investigators were invited to fill in the platform the new clinical data, vascular imaging, and therapeutic procedures, if any. The authors state that the study complies with the Declaration of Helsinki.

All inclusions were carefully checked by M.P., P.D., and/or A.P. and queries were sent to the centres as needed.

After resolution of all queries, the database was locked on 1 May 2019, exported, and analysed using R software version 3.2.2.10 Continuous variables were expressed as mean ± SD or median and interquartile range (IQR) according to their distribution; categorical variables were expressed as counts and percentage. Continuous variables were compared using the Student’s test or the Mann–Whitney test. Categorical variables were compared using the χ² test. A multinomial logistic regression (multivariate analysis) was performed to identify predictors of multivessel involvement, and of presence of FMD-related aneurysm and/or dissection, using both forward and backward methods. Multivariate analysis included all relevant variables [demographic features, inaugural manifestations of FMD (hypertension, stroke . . . ), FMD subtype, family history, and disease characteristics] shown to be significantly different in univariate analysis. A P value <0.05 was considered statistically significant.

### 3. Results

#### 3.1 Demographic and clinical characteristics

One thousand twenty-two patients were enrolled in 46 centres from 22 countries (five outside Europe, representing 11% of the whole series) between 1 December 2015 and 30 April 2019 (database lock). Mean age at FMD diagnosis was 46 ± 16 years, patients were predominantly women (82%), Caucasians (88%) and of the multifocal subtype (72%). About 86% (n = 864) of patients had hypertension. Nineteen% (n = 192) were smokers. The mean body mass index (BMI) and estimated glomerular filtration rate (eGFR) were 25 ± 5 kg/m² and 92 ± 40 mL/min/1.73 m² (CKD–EPI equation),11 respectively. Finally, only 3% of patients (n = 31) reported a family history of FMD (Table 1).

#### 3.2 FMD presenting symptoms and vascular bed involvement

Hypertension was the most frequent presenting symptom (72%). Seventeen% of patients (n = 170) were diagnosed with FMD after referral for pulsatile tinnitus, 12% (n = 117) for neurological symptoms (such as transient ischaemic attack—TIA, stroke, subarachnoid haemorrhage, and Claude Bernard–Horner syndrome), and 8% (n = 84) for headache. Finally, in 26 patients (3%), FMD was an incidental finding.

The prevalence of multivessel FMD, assessed in the subset of 488 patients who underwent full vascular screening (renal, cerebrovascular, and visceral/limb arteries) was 57% (n = 280). One hundred and eighty-two patients (37%) had FMD lesions in 2 vascular beds, 73 patients (15%) in 3 vascular beds, and 25 patients (5%) in 4 or more vascular beds. Among patients screened for each vascular bed, the proportion of patients with renal, cerebrovascular, visceral, and lower limb arteries FMD was 91%, 63%, 21%, and 31%, respectively (Table 1 and Figure 1).

### Table 1 Overall characteristics of patients enrolled in the European/International FMD Registry

<table>
<thead>
<tr>
<th>No. of patients analysed</th>
<th>1022</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age at diagnosis (years), mean ± SD</td>
<td>45.8 ± 15.9</td>
</tr>
<tr>
<td>Females (%)</td>
<td>0.831/1022 (81.5)</td>
</tr>
<tr>
<td>Caucasians (%)</td>
<td>0.885/1012 (87.5)</td>
</tr>
<tr>
<td>Systolic BP (mmHg), mean ± SD</td>
<td>139.7 ± 23.3</td>
</tr>
<tr>
<td>Diastolic BP (mmHg), mean ± SD</td>
<td>84.6 ± 14.4</td>
</tr>
<tr>
<td>Hypertension (%)</td>
<td>0.864/1008 (85.6)</td>
</tr>
<tr>
<td>Age at hypertension diagnosis (years), mean ± SD</td>
<td>37.1 ± 15.3</td>
</tr>
<tr>
<td>No. of antihypertensive drugs, median (IQR)</td>
<td>2 (1–3)</td>
</tr>
<tr>
<td>Current smokers (%)</td>
<td>0.192/1002 (19.3)</td>
</tr>
<tr>
<td>BMI, mean ± SD</td>
<td>24.5 ± 4.8</td>
</tr>
<tr>
<td>eGFR CKD–EPI (mL/min/1.73 m²), mean ± SD</td>
<td>91.8 ± 39.6</td>
</tr>
<tr>
<td>Presentation of FMD</td>
<td></td>
</tr>
<tr>
<td>Hypertension/renovascular presentation (%)</td>
<td>734/1018 (72.0)</td>
</tr>
<tr>
<td>Cerebrovascular presentation</td>
<td>171/1011 (11.6)</td>
</tr>
<tr>
<td>Stroke (%)</td>
<td>80/1011 (7.9)</td>
</tr>
<tr>
<td>TIA (%)</td>
<td>30/1011 (3.0)</td>
</tr>
<tr>
<td>Subarachnoid haemorrhage (%)</td>
<td>33/1011 (3.2)</td>
</tr>
<tr>
<td>Claude Bernard–Horner syndrome (%)</td>
<td>20/1011 (2.0)</td>
</tr>
<tr>
<td>Other presentations</td>
<td></td>
</tr>
<tr>
<td>Headache (%)</td>
<td>84/1004 (8.4)</td>
</tr>
<tr>
<td>Pulsatile tinnitus (%)</td>
<td>170/1004 (16.9)</td>
</tr>
<tr>
<td>Incidental finding (%)</td>
<td>26/1004 (2.6)</td>
</tr>
<tr>
<td>Multifocal FMD (%)</td>
<td>740 (72.3)</td>
</tr>
<tr>
<td>Coexisting atherosclerotic lesions (%)</td>
<td>171/1012 (16.9)</td>
</tr>
<tr>
<td>Multivessel FMD (%)</td>
<td>280/488 (57.4)</td>
</tr>
</tbody>
</table>

Numbers of patients (%) in whom lesions were found/numbers of patients (%) screened for each vascular bed

- **Renal arteries**: 855/943 (90.7)
- **Cerebrovascular arteries**: 391/625 (62.6)
- **Visceral arteries**: 161/760 (21.2)
- **Lower extremity arteries**: 87/283 (30.7)
- **At least one aneurysm in any vascular bed (%)**: 220/1019 (21.6)
- **At least one dissection in any vascular bed (%)**: 57/1021 (5.6)
- **At least one vascular bed treated with revascularization (%)**: 531/1022 (51.9)
- **Family history of FMD (%)**: 31/1018 (3.0)

BMI, body mass index; BP, blood pressure; CKD–EPI, Chronic Kidney Disease Epidemiology Collaboration; eGFR, estimated glomerular filtration rate; FMD, fibromuscular dysplasia; TIA, transient ischaemic attack.

1 Assessed in the subset of patients who underwent full vascular screening (renal, cerebrovascular, visceral/limb arteries).
The prevalence of FMD-related aneurysms and dissections in the whole cohort was of 22% and 6%, respectively. About 52% of patients (n = 531) underwent at least an endovascular and/or surgical intervention.

3.3 Subgroup analysis

3.3.1 Focal vs. multifocal FMD

Compared with patients with multifocal FMD (n = 740), patients with focal FMD (n = 282) were younger at diagnosis of FMD (39 ± 16 years vs. 49 ± 15, P value <0.001) and hypertension (32 ± 15 years vs. 39 ± 15, P value = 0.001) and more frequently males (31 vs. 14%, P value = 0.001) (Table 2). They also had a lower prevalence of multivessel (16% vs. 41%, P value = 0.001) and bilateral FMD, both in renal (21% vs. 41%, P value = 0.001) and cerebrovascular (11% vs. 29%, P value = 0.001) arterial beds. Finally, they had less aneurysms (11% vs. 26%, P value = 0.006) and coexisting atherosclerotic lesions (12% vs. 19%, P value = 0.008), but underwent more endovascular and/or surgical interventions (70% vs. 45%, P value = 0.001).

3.3.2 Men vs. women

Compared to women with FMD, men were significantly younger at diagnosis of both FMD (42 ± 17 vs. 47 ± 16 years, P value = 0.001) and hypertension (34 ± 16 vs. 38 ± 15 years, P value = 0.02), had more frequently focal FMD (46% vs. 23%, P value = 0.001) and less bilateral cerebrovascular lesions (17% vs. 26%, P value = 0.02) (Table 3). Furthermore, men had a higher prevalence of arterial dissections than women (14% vs. 4%, P value = 0.001), while no significant difference was found in terms of prevalence of arterial aneurysms (men: 19% vs. women: 22%, P value = 0.3).

3.3.3 Elderly patients

Compared to younger patients, patients ≥ 65 years old at diagnosis of FMD had more often multifocal FMD (85% vs. 71%, P value = 0.002) and

![Figure 1](https://academic.oup.com/cardiovascres/advance-article-abstract/doi/10.1093/cvr/cvaa102/5819550) Examples of FMD lesions in various arterial beds. (A) Multifocal stenosis of the right internal carotid artery, of the left vertebral artery and of the left internal carotid artery. (B) Multifocal stenosis of the mid–distal segment of the right renal artery. (C) Severe focal stenosis of the distal segment of the left renal artery. (D) Multifocal stenosis of the coeliac trunk. (E) Bilateral multifocal stenosis of iliac common arteries.
tended to have a more widespread disease (multivessel disease: 42% vs. 33%, \( P \) value = 0.08) (Table 3). Older patients also had a higher rate of coexisting atherosclerotic lesions (33% vs. 15%, \( P \) value = 0.004) but lower eGFR levels (69 ± 24 vs. 95 ± 40 mL/min/1.73 m², \( P \) value < 0.001). Finally, they underwent less interventional procedures (31% vs. 55%, \( P \) value = 0.001).

### 3.4 Predictors of Multivessel Disease, Aneurysms, and Dissections

We looked for predictors of multivessel disease (Table 4), aneurysms (Table 5), and dissections (Table 6), both in univariate and multivariate analysis.

In multivariate regression analysis (forward analysis), predictors of multivessel FMD were: age at diagnosis of FMD (OR/per year 1.02, 95% CI [1.00–1.03], \( P \) value = 0.001), stroke/cerebrovascular presentation (OR 2.42, 95% CI [1.39–4.18], \( P \) value = 0.001), eGFR (OR per ml/min 0.99, 95% CI [0.98–0.99], \( P \) value = 0.007), presence of at least one aneurysm (OR 4.31, 95% CI [3.05–6.13], \( P \) value < 0.001) or at least one dissection (OR 2.92, 95% CI [1.56–5.64], \( P \) value = 0.001) in any vascular bed, multivocal FMD (OR 3.00, 95% CI [2.03–4.55], \( P \) value = 0.001) and family history of FMD (OR 3.15, 95% CI [1.43–7.11], \( P \) value = 0.005).

Predictors of the presence of aneurysm were multivessel (OR 3.99, 95% CI [2.89–5.57], \( P \) value < 0.001) and multifocal (OR 1.91, 95% CI [1.26–2.98], \( P \) value = 0.003) FMD. Predictors of the presence of dissection were age at diagnosis of FMD (OR/per year 1.02, 95% CI [1.01–1.05], \( P \) value = 0.03), male gender (OR 4.35, 95% CI [2.33–7.69], \( P \) value = 0.005), stroke/cerebrovascular presentation (OR 2.19, 95% CI [1.01–4.52], \( P \) value = 0.04), and multivessel FMD (OR 3.15, 95% CI [1.74–5.87], \( P \) value = 0.001). In contrast, hypertension/renovascular presentation was negatively correlated both with presence of aneurysms (OR 0.63, 95% CI [0.42–0.96], \( P \) value = 0.03) and dissections (OR 0.30, 95% CI [0.16–0.56], \( P \) value = 0.001).

For all 3 analysis, the same predictors were identified using backward analysis (data not shown).

### 4. Discussion

We performed a detailed analysis of the first 1022 patients enrolled in the European/International FMD Registry, including 46 centres from 22 countries, with emphasis on comparison between different subsets of patients and predictors of widespread disease and complications.

First, we confirmed the distinctive features of focal vs. multifocal FMD, as established by Savard et al.\(^{12}\) Compared to patients with multifocal FMD, patients with focal FMD were 10 years younger, more frequently males and had a much lower prevalence of bilateral and multivessel FMD.

Secondly, in agreement with previous reports from large datasets, we documented a high prevalence of multivessel FMD: 57% in the European/International FMD Registry, vs. 66% in the French–Belgian ARCADIA Registry (48% not including aneurysms and dissections)\(^{6}\) and 55% in the last update of the US FMD Registry.\(^{2}\)

Third, we reported the characteristics and predictors of multivessel FMD. In agreement with the ARCADIA study,\(^{7}\) patients with multivessel disease were more likely to have multifocal FMD or stroke/cerebrovascular presentation. Intriguingly also, patients with multivessel disease were older than patients with single-vessel disease in both registries. Whether this reflects the progression of FMD from single-vessel to multivessel disease over time is currently unknown and is in contrast with expert opinion that de novo FMD lesions only seldom appear.\(^{13}\) Other additional predictors of multivessel FMD reported for the first time in...
this dataset include the presence of aneurysm (OR: 4.32) or dissection (OR 3.16) in at least one vascular bed, as well as family history of FMD (OR 3.00).

Fourth, we documented the prevalence of arterial aneurysms and dissections in our multicentre cohort. While the prevalence of aneurysms (21.6%) was similar to that observed in the US (22.7%)\(^2\) and ARCADIA (26.0%)\(^6\) registries, the prevalence of arterial dissections was substantially lower (5.6% vs. 28.1% and 15.1%, respectively), probably due to predominance of Hypertension/Nephrology centres with focus on renovascular FMD vs. Neurology centres dealing with carotid/vertebral dissections in our Registry.

Fifth, we reported for the first time—at least in Europe—predictors of aneurysms and dissections in a wide dataset of patients with FMD. With the exception of multivessel FMD, which was associated with both dissections and aneurysms, predictors of either complication were different: multifocal FMD for aneurysms vs. higher age at diagnosis and male gender for dissections. The latter is in agreement with the higher frequency of arterial dissection in men vs. women documented in the US.
FMD registry. This male predominance of (mostly carotid) dissection is in sharp contrast with the overwhelming female predominance of spontaneous coronary artery dissection, a disease often associated with extra-coronary FMD, showing that the association between dissection and gender may be vessel-specific.

Sixth, for the first time in Europe, we documented characteristics differentiating men vs. women and older vs. younger patients with FMD. Regarding gender differences, besides a higher prevalence of focal FMD and a four-fold increased prevalence of dissection in men, men were also slightly younger at diagnosis of FMD and hypertension and had a higher prevalence of stroke. These last findings are at odds with those of a preliminary report of the US Registry for FMD. They may partly reflect the fact that screening for FMD is less often performed in male than female patients, unless there is severe or early hypertension and/or cerebrovascular complications.

The proportion of patients diagnosed at 65 years or older was consistent with that of the US FMD Registry (12% vs. 16%). However, characteristics of older patients slightly differed between both registries. While European elderly patients differed from younger patients by a slightly lower prevalence of hypertension at diagnosis, higher age at hypertension diagnosis and a lower prevalence of active smoking, US elderly patients reported less often headache and pulsatile tinnitus compared to younger patients, and had an increased prevalence of hypertension but less arterial dissections. Again, to what extent this reflects differences in natural history and/or distinct referral and exploration biases in both registries deserves further investigation.

While the prevalence of atherosclerotic lesions was expectedly higher in older than younger patients enrolled in the European International FMD Registry, it remains surprisingly low (33%). As a matter of comparison, in the Cardiovascular Health Study, including 5888 participants aged ≥65 years, the prevalence of carotid atherosclerotic plaques was 77%. In agreement with the lower prevalence of cardiovascular events in elderly patients from the US Registry, this may reflect survival or inclusion biases. Alternatively, it may support the common belief that patients with FMD are somehow protected from arteriosclerosis.

### 3.5 Limitations

Our work has a number of limitations: (i) only 3% of cases of FMD were diagnosed incidentally. Therefore, our findings mostly apply to symptomatic FMD; (ii) non-Caucasian patients remain underrepresented (12.5%), though to a lesser extent than in the US Registry (8.7%); (iii) the contribution of regions of Europe such as Scandinavia, Germany, and Eastern Europe is still insufficient; (iv) Neurology centres remain a minority compared to Nephrology/Hypertension centres; (v) information on intake of antiplatelet agents—which was not recommended in Europe when the Registry was established—plasma lipids and fasting glycaemia/history of diabetes was not captured; (vi) only half of patients (48%) were explored for all vascular beds. However, the subgroup of fully explored patients did not differ from the other patients enrolled in the Registry, and predictors of multivessel FMD in the whole cohort were consistent with those identified in the subset of fully explored patients (data not shown);

### Table 5 Predictors of the presence of aneurysm in patients with FMD enrolled in the European/International FMD Registry

<table>
<thead>
<tr>
<th>Variable</th>
<th>Univariate analysis</th>
<th>Multivariate analysis</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Odds ratio (95% CI)</td>
<td>P value</td>
</tr>
<tr>
<td>Age at diagnosis of FMD*</td>
<td>1.01 (0.99–1.02)</td>
<td>0.06</td>
</tr>
<tr>
<td>Hypertension/renovascular presentation</td>
<td>0.57 (0.38–0.85)</td>
<td>0.002</td>
</tr>
<tr>
<td>Multivessel FMD</td>
<td>4.57 (3.33–6.27)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Multifocal FMD</td>
<td>3.03 (2.01–4.72)</td>
<td>0.001</td>
</tr>
<tr>
<td>At least one dissection in any vascular bed</td>
<td>1.57 (0.83–2.82)</td>
<td>0.03</td>
</tr>
</tbody>
</table>

FMD, fibromuscular dysplasia.

*OR per year.

### Table 6 Predictors of the presence of dissection in patients with FMD enrolled in the European/International FMD Registry

<table>
<thead>
<tr>
<th>Variable</th>
<th>Univariate analysis</th>
<th>Multivariate analysis</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Odds ratio (95% CI)</td>
<td>P value</td>
</tr>
<tr>
<td>Age at diagnosis of FMD*</td>
<td>1.03 (1.01–1.05)</td>
<td>0.001</td>
</tr>
<tr>
<td>Male gender</td>
<td>3.95 (2.24–6.94)</td>
<td>0.001</td>
</tr>
<tr>
<td>Hypertension/renovascular presentation</td>
<td>0.23 (0.13–0.42)</td>
<td>0.001</td>
</tr>
<tr>
<td>Stroke/neurovascular presentation</td>
<td>3.78 (1.83–7.32)</td>
<td>0.001</td>
</tr>
<tr>
<td>At least one aneurysm</td>
<td>1.57 (1.08–2.82)</td>
<td>0.03</td>
</tr>
<tr>
<td>Multivessel FMD</td>
<td>3.85 (2.19–6.97)</td>
<td>0.01</td>
</tr>
</tbody>
</table>

FMD, fibromuscular dysplasia.

*OR per year.
Typical features of patients with multifocal/focal FMD*, multivessel/single-vessel FMD, and FMD with aneurysm(s) or dissection(s) based on findings of the European / International FMD registry.

**Multifocal**
- Older age
- Female
- Multivessel
- Aneurysm(s)

**Focal**
- Younger age
- Male
- Single-vessel

**Multivessel**
- Older age
- Multifocal
- Aneurysm / Dissection

**Single-vessel**
- Younger age
- Focal

**Aneurysm**
- Multifocal
- Multivessel

**Dissection**
- Older age
- Male
- Multivessel

*FMD: Fibromuscular Dysplasia

**Figure 2** Typical features of patients with multifocal/focal FMD, multivessel/single-vessel FMD, and FMD with aneurysm(s) or dissection(s) based on findings of the European/International FMD Registry. FMD, fibromuscular dysplasia.

and (vii) finally, the current analysis is cross-sectional, therefore the course of the disease cannot be assessed and predictors of multivessel FMD, presence of aneurysms and dissections need confirmation in prospective studies.

### 3.6 Conclusion

The European/International FMD Registry is a unique resource incorporating patients from 46 centres from Europe and beyond vs. 16 for the French-Belgian ARCADIA study and 13 in the US Registry. This wide recruitment is expected to increase the generalizability and external validity of our findings. This first analysis including over 1000 patients allowed large-scale characterization of distinct profiles of patients with FMD and, more importantly, identification of a unique set of independent predictors of widespread disease, aneurysms and dissections (Figure 2), paving the way for targeted screening, management, and follow-up of FMD.
Beyond scientific findings, the involvement of a wide network of investigators in European/International FMD Registry will undoubtedly contribute to improve and harmonize screening and management of FMD across Europe and beyond, which will in its turn facilitate large-scale testing of new hypothesis and evaluation of different management strategies.

**Authors’ contributions**


**Acknowledgements**

A.P. wishes to acknowledge Prof. P.-F. Plouin, X. Jeunemaitre, and M. Azizi (HEGP, Paris, France) and Prof. A. Morganti (University of Milan, Milan, Italy) for their relentless support for the European/International FMD Registry and Initiative, as well as L. Toubiana (INSERM, UMR_S1142, LIMICS, Paris, France) for his crucial role in the establishment and update of the FMD platform. The authors are also deeply indebted to the leadership of the European Society of Hypertension (ESH) and the European Society for Vascular Medicine (ESVIM) for their constant support.

**Notes**

Investigators from the European/International FMD Registry and Initiative (FEIRI): Buenos Aires, Argentina). Investigators from the European/International FMD Registry and Initiative, as well as L. Toubiana (INSERM, UMR_S1142, LIMICS, Paris, France) for his crucial role in the establishment and update of the FMD platform. The authors are also deeply indebted to the leadership of the European Society of Hypertension (ESH) and the European Society for Vascular Medicine (ESVIM) for their constant support.

Beyond scientific findings, the involvement of a wide network of investigators in European/International FMD Registry will undoubtedly contribute to improve and harmonize screening and management of FMD across Europe and beyond, which will in its turn facilitate large-scale testing of new hypothesis and evaluation of different management strategies.
Infanta Cristina, Badajoz); Esteban Poch, Enrique Montagud-Marrahi, Alicia Molina, Elena Guillen (Department of Nephrology and Kidney Transplantation, University of Barcelona, Barcelona) and Marta Burrel (Department of Radiology, Hospital Clinic, Barcelona); Patricia Fernández De la Llana and Luis San Miguel-Amigo (Hypertension Unit, Nephrology Department, Fundación Puigvert, Barcelona); Antonio J Barros-Menembria (Cardiology Department, Hospital de la Santa Creu i Sant Pau, Barcelona); Sweden: Anders Gottsäter (Skåne University Hospital, Malmö, Sweden). Switzerland: Gregor Wuerzner (Service of Nephrology and Hypertension, Department of Medicine, Lausanne University Hospital – CHUV, Lausanne); Lucia Mazzolai and Giacomo Buso (Division of Angiology, Heart and Vessel Department, Lausanne University Hospital – CHUV, Centre of rare vascular diseases and RAVAD registry, Lausanne); Tunisia: Faical Jarra and Hanen Chaker (Service de Néphrologie, CHU Hédi Chaker, Sfax, Tunisia). United Kingdom: David Adam (University of Leicester and the NIHR Leicester Biomedical Research Centre, UK); Constantina Chrysochou (Salford Royal NHS Foundation Trust, The National Registry of Rare Kidney Diseases – RaDaR –, Greater Manchester); Neeraj Dhaun, Robert W. Hunter, Iain MacIntyre and David Webb (University of Edinburgh, Edinburgh).

Conflict of interest: none declared.

References


Translational perspective

Fibromuscular dysplasia (FMD) is nowadays considered as a systemic arterial disease, warranting brain-to-pelvis vascular imaging in all patients. However, most current evidence is derived from a limited number of expert centres. Furthermore, one size may not fit all. Based on analysis of the first 1000 patients enrolled in the European/International FMD registry (46 centres; 22 countries) we characterized distinct patient profiles according to FMD subtype, age and gender and identified predictors of widespread disease, aneurysms and dissections, paving the way for individualized management and follow-up. Further studies will allow refining patient characterization according to ethnicity, genetic profile, and imaging biomarkers.